Development of a medication review with follow-up guide on patients with epilepsy
DOI:
https://doi.org/10.30827/ars.v60i1.8019Keywords:
epilepsy, anticonvulsants, pharmaceutical services, medication review with follow-upAbstract
Aim: Prepare a document to conduct medication review with follow-up of patients diagnosed with epilepsy. This document is been addressed to every health professional who take care of the patient, especially to community pharmacists.
Method: A literature review has been performed over the available resources until 15 June 2017. The search strategy considers sources of evidence in epilepsy, pharmaceutical care and medication review with follow-up guides, human pharmacology and dispensing books, drugs databases and scientific evidence databases.
Results: In the application of the medication review with follow-up of patients with epilepsy, the treatment should be assessed through indicators of necessity (existence of a health problem that justifies the use of anticonvulsants), effectiveness (absence or decrease of the number of epileptic seizures) and safety (absence of adverse reactions, contraindications and interactions). This allows the appropriate co-design of an intervention strategy in collaboration with the patient and/or other health-care providers to improve the patients’ quality of life.
Conclusions: This guide includes detailed information about the epilepsy and the treatments used by considering the patient as a unit and not divided according to their health problems. Therefore, this guide could be a useful tool tailored to those pharmacists involved in the medication review with follow-up of patients with epilepsy.
Downloads
References
Sociedad Española de Neurología. Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012.1. Guía oficial de práctica clínica en epilepsia. Madrid: Luzán 5; 2012.
Scheffer IE, Berkovic S, Capovilla G, Conolly MB, French J, Guilhoto L et al. ILAE classification of the epilepsies: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–521. DOI: 10.1111/epi.13709.
Fisher RS, Cross JH, D’Souza C, French J, Haut SR, Higurashi N et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58(4):531–542. DOI: 10.1111/epi.13671.
García-Ramos R, García A, Masjuan J, Sánchez, C, Gil A. Informe FEEN sobre la epilepsia en España. Neurologia. 2011;26(9):548–555. DOI: 10.1016/j.nrl.2011.04.002.
Serrano-Castro PJ, Mauri-Llerda JA, Hernández-Ramos FJ, Sánchez-Álvarez JC, Parejo-Carbonell B, Quiroga-Subirana P et al. “Adult prevalence of epilepsy in Spain: EPIBERIA, a Population-Based Study”. Sci World J. 2015; 2015:1-8. DOI: 10.1155/2015/602710.
Agencia Española de Medicamentos y Productos Sanitarios, AEMPS. Utilización de medicamentos antiepilépticos en España durante el periodo 2008-2016. Madrid: AEMPS; 2017. Informe de utilización de medicamentos U/EPIL/V1/11/09/2017.
Sabater D, Silva MM, Faus MJ. Método Dáder: Guía de Seguimiento Farmacoterapéutico. 3a ed. Grupo de investigación en Atención Farmacéutica (GIAF), editor. Granada; 2007.
Grupo de investigación en Atención Farmacéutica de la Universidad de Granada: conSIGUE. Programa para la implantación y futura sostenibilidad del servicio de seguimiento farmacoterapéutico en la farmacia comunitaria española. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF); 2016. Informe 2014-2016.
Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada: conSIGUE. Medida del impacto clínico, económico y humanístico del servicio de seguimiento farmacoterapéutico en mayores polimedicados en la farmacia comunitaria española. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF); 2014. Informe 2011-2014.
Vargas CM, Vacca CP, Simbaqueba JB. Variables psicosociales en el seguimiento farmacoterapéutico de personas con epilepsia en Colombia. Vitae-Columbia. 2012; 19(3):270-279.
Baker GA. People with epilepsy: What do they know and understand, and how does this contribute to their perceived level of stigma? Epilepsy Behav. 2002;3 (6):26-32. DOI: 10.1016/S1525-5050(02)00544-9.
Osungbade KO, Siyanbade SL. Myths, misconceptions, and misunderstandings about epilepsy in a Nigerian rural community: Implications for community health interventions. Epilepsy Behav. 2011;21(4):425-429. DOI: 10.1016/j.yebeh.2011.05.014.
Goldstein LH, Minchin L, Stubbs P, Fenwick PB. Are what people know about their epilepsy and what they want from an epilepsy service related? Seizure. 1997;6 (6):436-442. DOI: 10.1016/S1059-1311(97)80017-9.
Coker MF, Bhargava S, Fitzgerald M, Doherty CP. What do people with epilepsy know about their condition? Evaluation of a subspecialty clinic population. Seizure. 2011;20(1):55-59. DOI: 10.1016/j.seizure.2010.10.007,
Fogg A, Staufenberg EF, Small I, Bhattacharya D. An exploratory study of primary care pharmacist-led epilepsy consultations. Int J Pharm Pract. 2012; 20:294-302. DOI: 10.1111/j.2042-7174.2012.00207.x.
Miranda G, Martínez FN, Arceo ME. La calidad de vida de los pacientes epilépticos determinada por la aplicación de la escala QOLIE-31. Neurol Neurocir Psiquat. 2007; 40(2):50-55.
Stanaway LLD, Johnson RH. Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J. 1985;98:150-152.
Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimen. Seizure. 1997;6:87-93. DOI: 10.1016/S1059-1311(97)80060-X.
Poole K, Moran N, Bell G, Solomon J, Kendall S, McCarty M et al. Patients’ perspectives on services for epilepsy; a survey of patients satisfaction, preferences and information provision in 2394 people with epilepsy. Seizure. 2000;9:551-558. DOI: 10.1053/seiz.2000.0450.
Couldridge L, Kendall S, March A. A systematic overview. A decade of research: the information counselling needs of people with epilepsy. Seizure. 2001; 10:605-614. DOI: 10.1053/seiz.2001.0652.
Koshy S. Role of pharmacists in the management of patients with epilepsy. Int J Pharm Pract. 2011;20:65-68. DOI: 10.1111/j.2042-7174.2011.00156.x.
Losada-Camacho M, Guerrero-Pabon MF, García-Delgado P, Martinez-Martinez F. Impact of a pharmaceutical care programme on health-related quality of life among women with epilepsy: a randomised controlled trial (IPHIWWE study). Health Qual Life Out. 2014;12(1):162. DOI: 10.1186/s12955-014-0162-8.
Kanjanasilp J, Peechagoon Y, Kaewvichit S, Richards RME. Pharmaceutical care improved outcomes in epileptic patients. CMU J Nat Sci. 2008; 7(1):33-45.
Yue L, Yu P, Zhao D, Wu D, Zhu G, Wu X et al. Determinants of quality of life in people with epilepsy and their gender differences. Epilepsy Behav. 2011; 22:692-696. DOI: 10.1016/j.yebeh.2011.08.022.
Shorvon S, Luciano AL. Prognosis of chronic and newly diagnosed epilepsy revisiting temporal aspects. Curr Opin Neurol. 2007;20:208–212. DOI: 10.1097/WCO.0b013e3280555175.
Sillanpäa M, Schmidt D. Early seizure and frequency aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain. 2009;132:989–998. DOI: 10.1093/brain/awn357.
Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B et al. Course and outcome of chilhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Chilhood. Epilepsia. 2010;51(7):1189-1197. DOI: 10.1111/j.1528-1167.2010.02546.x.
Marson A. When to start antiepileptic drug treatment and with what evidence? Epilepsia. 2008;48:140–147. DOI: 10.1111/j.1528-1167.2008.01920.x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Laura Torralba Fernández, Noelia Amador Fernández
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
